Eliem Therapeutics (ELYM) has shared an announcement.
Eliem Therapeutics, Inc. has appointed Brett Kaplan, M.D., as its Chief Operating Officer, effective August 26, 2024. Dr. Kaplan, with a solid background in finance and biotechnology, previously held leadership roles at Chroma Medicine, Prevail Therapeutics, and Evercore Partners. Under the terms of his employment, he will receive a $500,000 base salary, up to a 45% annual bonus, and equity in the form of stock options and restricted stock units. His compensation package also includes standard employee benefits and specific severance terms if employment ends under certain conditions.
Learn more about ELYM stock on TipRanks’ Stock Analysis page.
